OXIDATIVE CELL INJURY: FIRST-EPISODE PSYCHOTIC PATIENTS

氧化细胞损伤:首发精神病患者

基本信息

  • 批准号:
    6534551
  • 负责人:
  • 金额:
    $ 20.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-30 至 2004-08-31
  • 项目状态:
    已结题

项目摘要

The objective of this proposal is to establish that the increased oxidative cell injury exists at the onset of psychosis and probably continued injury contributes to poor outcome of illness in some patients. The basis of this proposal is the initial findings from our previous studies of an impaired antioxidant defense and increased lipid peroxidation that were associated with the brain morphometric changes at the onset of psychosis. The proposed studies are an extension to examine in a systematic way the presence and extent of oxidative cell injury in periphery and its relationship to relevant neuropathology and neurotransmitter receptor-mediated signal transduction, and to elucidate the clinical implications in patients with a first episode of psychosis. The 4 year study will involve 40 first-episode psychosis patients at the D. D. Eisenhower Army Medical Center and 40 normal controls matched with patients for age, gender, education, ethnic background, and occupational status. Effects of oxidative cell injury will be examined in lymphocyte plasma membrane lipids, mitochondrial membranes, cellular proteins, and DNA (both Mitochondrial and nuclear). Specific measures will include membrane lipid peroxidation products (malondialdehyde, MDA), phospholipase A2 (PLA2), conjugated dienes and fatty acid contents, levels of carbonylated proteins, and DNA strand breaks. Activities of antioxidant enzymes (superoxide dismutase, glutathione peroxidase, and catalase) will be determined in red blood cells and in lymphocyte mitochondria. Plasma levels of MDA, PLA2, nonenzymatic antioxidants (vitamins C and E, urate), and micronutrients (copper, zinc, selenium) that are involved in activities of antioxidant enzymes will also be determined. Measures of antioxidants and indices of oxidative injury will be repeated after 6 and 12 weeks of neuroleptic treatment. Correlational studies will be conducted to examine the relationships of specific indices o oxidative injury with clinical parameters (history of premorbid functioning, severity of psychosis and negative symptoms at initial presentation, neurological signs, quality of immediate treatment response, early recurrence of psychosis after initial recovery, residual symptoms after three months of treatment, etc.), brain morphology using magnetic resonance imaging, and levels of neurotransmitter receptor-mediated phospholipid-derived release of second messengers (e.g., arachidonic acid and inositol polyphosphates). These studies will, albeit in peripheral cells, define the extent and nature of oxidative cell injury that will reflect the brain neuropathology associated with psychopathology at the onset of psychosis. If it is demonstrated in this comprehensive study that oxidative injury at the onset of psychosis contributes to a unfavorable early course of illness, it would suggest the need for adjunctive antioxidant treatment from the onset of psychosis. Studies on the nature of oxidative injury might then provide directions for developing rational and effective treatment strategies. Conceivably these could reduce the costs of clinical care by lowering risk of relapse and, hopefully, even prevent a deteriorating course of illness in some patients.
本提案的目的是确定在精神病发作时存在增加的氧化性细胞损伤,并且可能持续的损伤导致某些患者的疾病预后不良。 这一建议的基础是我们以前的研究的初步发现,抗氧化防御受损和脂质过氧化作用增加,与精神病发作时的脑形态学变化有关。拟议的研究是一个扩展,以系统的方式检查周围的氧化性细胞损伤的存在和程度及其与相关的神经病理学和神经递质受体介导的信号转导的关系,并阐明首次发病的精神病患者的临床意义。 这项为期4年的研究将涉及40名在D。D.艾森豪威尔陆军医学中心和40名正常对照组与患者的年龄,性别,教育,种族背景和职业地位相匹配。将在淋巴细胞质膜脂质、线粒体膜、细胞蛋白和DNA(线粒体和核)中检查氧化性细胞损伤的影响。 具体措施将包括膜脂质过氧化产物(丙二醛)、磷脂酶A2(PLA2)、共轭二烯和脂肪酸含量、羰基化蛋白水平和DNA链断裂。 将在红细胞和淋巴细胞线粒体中测定抗氧化酶(超氧化物歧化酶、谷胱甘肽过氧化物酶和过氧化氢酶)的活性。还将测定MDA、PLA2、非酶抗氧化剂(维生素C和E、尿酸盐)和参与抗氧化酶活性的微量营养素(铜、锌、硒)的血浆水平。 抗氧化剂和氧化损伤指数的测量将在抗精神病药物治疗6周和12周后重复。 将进行相关性研究,以检查氧化损伤的特定指标与临床参数(病前功能史、精神病严重程度和初始表现时的阴性症状、神经系统体征、立即治疗反应的质量、初始恢复后精神病的早期复发、治疗3个月后的残留症状等)的关系,使用磁共振成像的脑形态,和神经递质受体介导的磷脂衍生的第二信使释放的水平(例如,花生四烯酸和肌醇多磷酸)。这些研究将,虽然在外周细胞,定义氧化性细胞损伤的程度和性质,将反映与精神病发作时的精神病理学相关的脑神经病理学。如果在这项综合性研究中证明,精神病发作时的氧化损伤有助于不利的早期病程,则表明需要从精神病发作开始进行连续的抗氧化治疗。 对氧化损伤性质的研究可能为制定合理有效的治疗策略提供指导。可以想象,这些可以通过降低复发的风险来降低临床护理的成本,甚至有希望防止某些患者的疾病恶化。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome.
精神分裂症中载脂蛋白 D 血浆水平升高及其治疗和结果。
  • DOI:
    10.1016/s0920-9964(01)00378-4
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
    Mahadik,SahebaraoP;Khan,MohammadM;Evans,DeniseR;Parikh,VinayV
  • 通讯作者:
    Parikh,VinayV
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SAHEBARAO P MAHADIK其他文献

SAHEBARAO P MAHADIK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SAHEBARAO P MAHADIK', 18)}}的其他基金

OXIDATIVE CELL INJURY: FIRST-EPISODE PSYCHOTIC PATIENTS
氧化细胞损伤:首发精神病患者
  • 批准号:
    6375413
  • 财政年份:
    1999
  • 资助金额:
    $ 20.59万
  • 项目类别:
OXIDATIVE CELL INJURY: FIRST-EPISODE PSYCHOTIC PATIENTS
氧化细胞损伤:首发精神病患者
  • 批准号:
    6171949
  • 财政年份:
    1999
  • 资助金额:
    $ 20.59万
  • 项目类别:
OXIDATIVE CELL INJURY: FIRST EPISODE PSYCHOTIC PATIENTS
氧化细胞损伤:首发精神病患者
  • 批准号:
    2612155
  • 财政年份:
    1999
  • 资助金额:
    $ 20.59万
  • 项目类别:
NEUROTRANSMITTER SIGNAL TRANSDUCTION IN SCHIZOPHRENIA
精神分裂症的神经递质信号转导
  • 批准号:
    2042583
  • 财政年份:
    1998
  • 资助金额:
    $ 20.59万
  • 项目类别:
ABNORMALITIES IN FIBROBLASTS OF SCHIZOPHRENIC PATIENTS
精神分裂症患者成纤维细胞异常
  • 批准号:
    3429358
  • 财政年份:
    1992
  • 资助金额:
    $ 20.59万
  • 项目类别:
ABNORMALITIES IN FIBROBLASTS OF SCHIZOPHRENIC PATIENTS
精神分裂症患者成纤维细胞异常
  • 批准号:
    3429357
  • 财政年份:
    1992
  • 资助金额:
    $ 20.59万
  • 项目类别:
ABNORMALITIES IN FIBROBLASTS OF SCHIZOPHRENIC PATIENTS
精神分裂症患者成纤维细胞异常
  • 批准号:
    3429356
  • 财政年份:
    1991
  • 资助金额:
    $ 20.59万
  • 项目类别:

相似海外基金

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10661090
  • 财政年份:
    2022
  • 资助金额:
    $ 20.59万
  • 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10501196
  • 财政年份:
    2022
  • 资助金额:
    $ 20.59万
  • 项目类别:
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
使用非典型抗精神病药物治疗的患者诱导代谢综合征的可能作用机制
  • 批准号:
    22590157
  • 财政年份:
    2010
  • 资助金额:
    $ 20.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The use of atypical antipsychotic agents and the risk of breast cancer
非典型抗精神病药物的使用和乳腺癌的风险
  • 批准号:
    192724
  • 财政年份:
    2009
  • 资助金额:
    $ 20.59万
  • 项目类别:
    Operating Grants
Indolobenzox- and Thiazepines as Atypical Antipsychotic Agents
吲哚苯氧和硫氮卓类药物作为非典型抗精神病药
  • 批准号:
    7539253
  • 财政年份:
    2008
  • 资助金额:
    $ 20.59万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7676049
  • 财政年份:
    2007
  • 资助金额:
    $ 20.59万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7626881
  • 财政年份:
    2007
  • 资助金额:
    $ 20.59万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7333930
  • 财政年份:
    2007
  • 资助金额:
    $ 20.59万
  • 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
  • 批准号:
    7034693
  • 财政年份:
    2006
  • 资助金额:
    $ 20.59万
  • 项目类别:
Muscarinic receptor activators as novel antipsychotic agents
毒蕈碱受体激活剂作为新型抗精神病药
  • 批准号:
    7163800
  • 财政年份:
    2006
  • 资助金额:
    $ 20.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了